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ABSTRACT
Objectives To evaluate the individual risk factors
composing the CHADS2 (Congestive heart failure,
Hypertension, Age≥75 years, Diabetes, previous Stroke)
scoreandtheCHA2DS2-VASc(CHA2DS2-Vasculardisease,
Age 65-74 years, Sex category) score and to calculate the
capability of the schemes to predict thromboembolism.
Design Registry based cohort study.
Setting Nationwide data on patients admitted to hospital
with atrial fibrillation.
Population All patients with atrial fibrillation not treated
withvitaminKantagonistsinDenmarkintheperiod1997-
2006.
Main outcome measures Stroke and thromboembolism.
Results Of 121280 patients with non-valvular atrial
fibrillation, 73538 (60.6%) fulfilled the study inclusion
criteria. In patients at “low risk” (score=0), the rate of
thromboembolism per 100 person years was 1.67 (95%
confidence interval 1.47 to 1.89) with CHADS2 and 0.78
(0.58to1.04)withCHA2DS2-VAScatoneyear’sfollow-up.
In patients at “intermediate risk” (score=1), this rate was
4.75 (4.45 to 5.07) with CHADS2 and 2.01 (1.70 to 2.36)
with CHA2DS2-VASc. The rate of thromboembolism
depended on the individual risk factors composing the
scores, and both schemes underestimated the risk
associated with previous thromboembolic events. When
patients were categorised into low, intermediate, and
high risk groups, C statistics at 10 years’ follow-up were
0.812 (0.796 to 0.827) with CHADS2 and 0.888 (0.875 to
0.900) with CHA2DS2-VASc.
Conclusions The risk associated with a specific risk
stratification score depended on the risk factors
composing the score. CHA2DS2-VASc performed better
thanCHADS2inpredictingpatientsathighrisk,andthose
categorisedaslowriskbyCHA2DS2-VAScweretrulyatlow
risk for thromboembolism.
INTRODUCTION
Patientswithatrialfibrillationhaveasubstantialriskof
stroke,whichismodifiedbythepresenceorabsenceof
severalriskfactors.
12Theseriskfactorshavebeenused
to develop thromboembolic risk stratification
schemes, which have somewhat arbitrarily divided
the risk of thromboembolism into low, intermediate,
and high risk strata.
3 Given the limitations of oral anti-
coagulationtreatmentwithvitaminKantagonists,such
risk stratification allows clinicians to target patients at
“high risk” for treatment with vitamin K antagonists.
For the intermediate risk category, guidelines recom-
mend treatment with vitamin K antagonists or aspirin,
and aspirin is recommended for the low risk category.
Schemes for stratifying the risk of stroke have been
largely derived from non-anticoagulated arms of clin-
ical trial cohorts, in which many potential thrombo-
embolic risk factors were not recorded. In these
historical trials, less than 10% of patients screened
were randomised, and over the past 15-20 years the
evolution of risk schemes has not improved their pre-
dictivevalueforpatientsathighrisk.
4Morerecentdata
in patients at intermediate risk show that vitamin K
antagonists are superior to aspirin in reducing the risk
ofthromboembolismandadverseevents,
5-7andaspirin
does not reduce the risk of thromboembolism in atrial
fibrillationpatientsat“lowrisk”.
8Thus,aparadigmshift
has beenproposedwhereby greaterefforts are madeto
identify“trulylowrisk”patientswhomaynotneedany
antithrombotic treatment, whereas all others could be
considered for oral anticoagulation.
8-10
The most commonly used scheme for stratifying the
riskofstrokeistheCHADS2(Congestiveheartfailure,
Hypertension, Age≥75 years, Diabetes mellitus, pre-
vious Stroke/transient ischaemic attack (doubled risk
weight)) score.
11 Various limitations of this score have
been discussed, including classification of a large pro-
portion of patients as being at “intermediate risk” and
its omission of many potential thromboembolic risk
factors.
10 The 2006 ACC/AHA/ESC guideline listed
these potential additional risk factors as being “less
validated or weaker risk factors,” including female
sex, age 65-74 years, coronary artery disease, and
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12 Since 2006, stronger evidence has
accumulated that these additional risk factors (with
the exception of thyrotoxicosis) should be considered
in assessing thromboembolic risk and would be of
value in identifying those patients at truly low risk.
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The additional risk factors have been expressed in the
CHA2DS2-VASc(Congestiveheartfailure,Hyperten-
sion, Age≥75 years, Diabetes mellitus, previous
Stroke/transient ischaemic attack, Vascular disease,
Age 65-74 years, Sex category; age≥75 years and pre-
vious stroke carry doubled risk weight) score, which
has been proposed to complement the CHADS2
score.
13 In the original validation study from the Euro-
Heartsurvey,CHA2DS2-VAScgenerallyhadasimilar
Cstatisticto CHADS2 butwasbetteratidentifyingthe
patients at truly low risk and categorised only a small
proportion into the intermediate risk category.
13 In a
furtherstudyinasmallelderly“realworld”cohortwith
anticoagulated atrial fibrillation, the CHADS2 and
CHA2DS2-VASc had similar strength (C statistics)
for predicting thromboembolism.
14
An ideal validation cohort for a thromboembolic
risk scheme would be a large real world cohort of
patients with atrial fibrillation, without any use of anti-
coagulation treatment. In Denmark, the national
patientregistryallowssuchananalysisinalargecohort
ofrealworldpatients,andthefirstobjectiveoftheana-
lysis reported here was to assess the effects of the indi-
vidual factors of CHADS2 and CHA2DS2-VASc on
the risk of thromboembolism. Secondly, we evaluated
the predictive capability of CHADS2 and CHA2DS2-
VASc for thromboembolism.
METHODS
Registry data sources
In Denmark, all citizens have a permanent and perso-
nal registration number that enables linkage of the
nationwide registries at an individual level. Since
1978, all admissions from Danish hospitals have been
registered in the Danish national patient registry with
one primary discharge diagnosis and, if appropriate,
one or more secondary discharge diagnoses according
to ICD-8 (international classification of diseases, 8th
revision) up to 1993 and the ICD-10 from 1994
onwards.
15 From 1996, invasive therapeutic proce-
dures(suchassurgeryandpercutaneousinterventions)
havebeen codedaccordingtothe NordicMedicalSta-
tistics Committees Classification of Surgical Proce-
dures. Since 1995, all prescriptions dispensed from
Danish pharmacies have been accurately registered
in the Danish registry of medicinal product statistics
(prescription registry) according to the international
anatomical therapeutic chemical classification
system.
16 The civil registration system holds informa-
tion on vital status for all citizens, and the national
causes of death registry holds information on primary
and contributing causes of death.
Study population
From the national patient registry, we identified all
patients with non-valvular atrial fibrillation or atrial
flutter in the period 1997-2006. We defined non-
valvular atrial fibrillation by a discharge diagnosis of
atrial fibrillation or atrial flutter (diagnosis code I48),
no previous diagnoses of mitral or aortic valve disease
(394-396,4240,4241,I05,I06,I34,I35),andnomitral
oraorticvalvesurgery(surgicalprocedurecodesKFK,
KFM, KFP), as done previously.
17 Because drug treat-
ment may be changed or intensified in relation to hos-
pital admission, we started follow-up seven days after
discharge. We excluded patients if they died or had a
Table 1 |Baseline characteristics of patients. Values are numbers (percentages)
Characteristics
Patients discharged
with non-valvular AF
(n=121 280)
Patients who
survived 7 days
(n=118 243)
Patients who did not
receiveVKAorheparin
(study population)
(n=73 538)
Heart failure 22 759 (18.8) 22 082 (18.7) 13 126 (17.9)
Hypertension 48 171 (39.7) 47 224 (39.9) 25 060 (34.1)
Age ≥75 years 65 512 (54.0) 63 292 (53.5) 43 864 (59.7)
Age 65-74 years 29 367 (24.2) 28 817 (24.4) 14 544 (19.8)
Diabetes mellitus 11 072 (9.1) 10 754 (9.1) 6 496 (8.8)
Previous thromboembolism* 23 528 (19.4) 22 291 (18.9) 13 368 (18.2)
Vascular disease 20 305 (16.7) 19 568 (16.6) 12 873 (17.5)
Female sex 56 490 (46.6) 54 869 (46.4) 37 651 (51.2)
CHADS2 score:
0 26 139 (21.6) 25 863 (21.9) 16 406 (22.3)
1 38 024 (31.4) 37 225 (31.5) 23 730 (32.3)
2 28 249 (23.3) 27 540 (23.3) 16 393 (22.3)
3 18 198 (15.0) 17 477 (14.8) 10 846 (14.8)
4 8 178 (6.7) 7 760 (6.6) 4 745 (6.5)
5 2 210 (1.8) 2 110 (1.8) 1 260 (1.7)
6 282 (0.2) 268 (0.2) 158 (0.2)
CHA2DS2-VASc score:
0 10 125 (8.4) 10 065 (8.5) 6 369 (8.7)
1 14 526 (12.0) 14 376 (12.2) 8 203 (11.2)
2 22 115 (18.2) 21 726 (18.4) 12 771 (17.4)
3 27 834 (23.0) 27 152 (23.0) 17 371 (23.6)
4 22 676 (18.7) 21 995 (18.6) 13 887 (18.9)
5 14 213 (11.7) 13 639 (11.5) 8 942 (12.2)
6 6 927 (5.7) 6 586 (5.6) 4 244 (5.8)
7 2 327 (1.9) 2 194 (1.9) 1 420 (1.9)
8 467 (0.4) 443 (0.4) 285 (0.4)
9 70 (0.1) 67 (0.1) 46 (0.1)
Drugs:
α adrenergic blocker 1 729 (1.4) 1 681 (1.4) 1 005 (1.4)
Non-loop diuretic 37 292 (30.8) 36 319 (30.7) 21 695 (29.5)
Vasodilator 3 769 (3.1) 3 659 (3.1) 2 329 (3.2)
β blocker 50 370 (41.5) 49 611 (42.0) 26 160 (35.6)
Calcium channel blocker 35 235 (29.1) 34 539 (29.2) 18 966 (25.8)
Renin-angiotensin system inhibitor 33 445 (27.6) 32 731 (27.7) 16 868 (22.9)
Loop diuretic 47 676 (39.3) 46 340 (39.2) 27 602 (37.5)
Statin 13 629 (11.2) 13 372 (11.3) 6 919 (9.4)
Antiplatelet drug 38 007 (31.3) 37 047 (31.3) 25 503 (34.7)
Digoxin 60 661 (50.0) 59 547 (50.4) 31 418 (42.7)
Amiodarone 3 879 (3.2) 3 825 (3.2) 1 874 (2.6)
AF=atrial fibrillation; VKA=vitamin K antagonist.
*Includes peripheral artery embolism, transient ischaemic attack, ischaemic stroke, and pulmonary embolism.
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iod.Weidentifieddrugtreatmentstatusfromprescrip-
tion claims from 180 days before discharge to seven
days after discharge, and we excluded patients if they
had received vitamin K antagonists (medicine code
B01AA) or heparins (B01AB) (fig 1). We censored
patients at time of death or at the end of the follow-up
periods—that is, at one, five, and 10 years.
Covariates of CHADS2 and CHA2DS2-VASc
We identified patients with congestive heart failure
from the combination of a previous diagnosis of heart
failure (425, 4270, 4271, I110, I42, I50, J819) in the
nationalpatientregistryandtreatmentwithloopdiure-
tics(C03C).
18Weidentifiedpatientswithhypertension
from combination treatment with at least two of the
following classes of antihypertensive drugs: α adrener-
gic blockers (C02A, C02B, C02C), non-loop diuretics
(C02DA, C02L, C03A, C03B, C03D, C03E, C03X,
C07C, C07D, C08G, C09BA, C09DA, C09XA52),
vasodilators (C02DB, C02DD, C02DG, C04, C05), β
blockers (C07), calcium channel blockers (C07F, C08,
C09BB,C09DB),andrenin-angiotensinsysteminhibi-
tors (C09). This definition of hypertension was vali-
dated in a previously described randomly selected
cohort of people from the Danish population aged
16 years and older.
19 Of the 14994 people in this
cohort, 2028 reported having taken drugs for hyper-
tension within a two week period before the interview.
The positive predictive value of treatment with two
classes of antihypertensive drugs to predict hyperten-
sion was 80.0%, and the specificity was 94.7%. We
defined diabetes mellitus as a claimed prescription for
a glucose lowering drug (A10). Information on pre-
vious thromboembolism—that is, peripheral artery
embolism, stroke, transient ischaemic attack, and pul-
monary embolism (433-438, 444, 450, G458, G459,
I26,I63,I64,I74)—camefromthenationalpatientreg-
istry (from 1978), as did information on previous vas-
cular disease—that is, myocardial infarction,
peripheral artery disease, and aortic plaque (410, 440,
I21, I22, I700, I702-I709), as defined by Lip and
colleagues.
1320-23
The CHADS2 score was the sum of points obtained
afteradditionofonepointeachforheartfailure,hyper-
tension, age≥75, and diabetes and two points for pre-
vious thromboembolism. This score thus ranged from
0t o6 .
11 The CHA2DS2-VASc score was the sum of
pointsafteradditionofonepointeachforheartfailure,
hypertension, diabetes, vascular disease, age
65-74 years, and female sex and two points each for
previous thromboembolism and age≥75 years. This
score thus ranged from 0 to 9.
13 In both risk schemes,
we considered a score of 0 to represent low risk, 1 to
represent intermediate risk, and ≥2 to represent high
risk of thromboembolism.
Outcomes
Theprimarystudyendpointwasadmissiontohospital
withordeathfromthromboembolism—thatis,periph-
eral artery embolism, ischaemic stroke, or pulmonary
embolism (I26, I63, I64, I74), as defined by Lip and
colleagues.
13 We also did a sensitivity analysis confin-
ing the primary study end point to peripheral artery
Table 2 |Event rate (95% CI) of hospital admission and death due to thromboembolism* per
100 person years
Score/risk category 1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
CHADS2:
0 1.67 (1.47 to 1.89) 1.28 (1.19 to 1.38) 1.24 (1.16 to 1.33)
1 4.75 (4.45 to 5.07) 3.70 (3.55 to 3.86) 3.56 (3.42 to 3.70)
2 7.34 (6.88 to 7.82) 5.58 (5.35 to 5.83) 5.40 (5.18 to 5.63)
3 15.47 (14.62 to 16.36) 10.29 (9.87 to 10.73) 9.89 (9.50 to 10.31)
4 21.55 (20.03 to 23.18) 14.00 (13.22 to 14.82) 13.70 (12.95 to 14.48)
5 19.71 (16.93 to 22.93) 12.98 (11.52 to 14.63) 12.57 (11.18 to 14.14)
6 22.36 (14.58 to 34.30) 16.75 (11.91 to 23.56) 17.17 (12.33 to 23.92)
CHADS2:
Low risk (0) 1.67 (1.47 to 1.89) 1.28 (1.19 to 1.38) 1.24 (1.16 to 1.33)
Intermediate risk (1) 4.75 (4.45 to 5.07) 3.70 (3.55 to 3.86) 3.56 (3.42 to 3.70)
High risk (2-6) 12.27 (11.84 to 12.71) 8.30 (8.08 to 8.51) 7.97 (7.77 to 8.17)
CHA2DS2-VASc:
0 0.78 (0.58 to 1.04) 0.69 (0.59 to 0.81) 0.66 (0.57 to 0.76)
1 2.01 (1.70 to 2.36) 1.51 (1.37 to 1.67) 1.45 (1.32 to 1.58)
2 3.71 (3.36 to 4.09) 3.01 (2.83 to 3.20) 2.92 (2.76 to 3.09)
3 5.92 (5.53 to 6.34) 4.41 (4.21 to 4.61) 4.28 (4.10 to 4.47)
4 9.27 (8.71 to 9.86) 6.69 (6.41 to 6.99) 6.46 (6.20 to 6.74)
5 15.26 (14.35 to 16.24) 10.42 (9.95 to 10.91) 9.97 (9.53 to 10.43)
6 19.74 (18.21 to 21.41) 12.85 (12.07 to 13.69) 12.52 (11.78 to 13.31)
7 21.50 (18.75 to 24.64) 13.92 (12.49 to 15.51) 13.96 (12.57 to 15.51)
8 22.38 (16.29 to 30.76) 14.07 (10.80 to 18.33) 14.10 (10.90 to 18.23)
9 23.64 (10.62 to 52.61) 16.08 (8.04 to 32.15) 15.89 (7.95 to 31.78)
CHA2DS2-VASc:
Low risk (0) 0.78 (0.58 to 1.04) 0.69 (0.59 to 0.81) 0.66 (0.57 to 0.76)
Intermediate risk (1) 2.01 (1.70 to 2.36) 1.51 (1.37 to 1.67) 1.45 (1.32 to 1.58)
High risk (2-9) 8.82 (8.55 to 9.09) 6.01 (5.88 to 6.14) 5.72 (5.60 to 5.84)
*Includes peripheral artery embolism, ischaemic stroke, and pulmonary embolism.
Patients discharged with non-valvular atrial
fibrillation in period 1997-2006 (n=121 280)
Entered 7 day quarantine period (n=121 096, 99.8%)
Survived 7 days from discharge (n=118 243, 97.5%)
Excluded because of discharge within 7 days
from 31 December 2006 (n=184, 0.2%)
Excluded (n=2853, 2.4%):
  Died within 7 days from discharge (n=2022)
  Thromboembolism within 7 days from
    discharge (n=831)
Final study population (n=73 538, 60.6%)
Excluded (n=44 705, 37.8%):
  Received vitamin K antagonist (n=44 605)
  Received heparin (n=100)
Fig 1 | Flow chart of study population
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monaryembolism).Thesecondaryoutcomewasdeath
from any cause.
Statistical analysis
In patients discharged with non-valvular atrial fibrilla-
tion who were not receiving treatment with vitamin K
antagonists or heparins, we estimated event rates for
thromboembolism and death for the various
CHADS2andCHA2DS2-VAScscoresandforthespe-
cific covariate combinations forming the scores of 1 or
2.Weestimatedtheriskofthromboembolismbyusing
Cox proportional hazard regression models. In the
Cox models, we analysed the risk associated with all
possible risk factor combinations for CHADS2
score=1 (four combinations) and CHADS2 score=2
(seven combinations); we used CHADS2 score=0a s
the reference. In the same manner, other Cox models
analysedtheriskassociatedwithallpossibleriskfactor
combinations for CHA2DS2-VASc score=1 (six com-
binations)andCHA2DS2-VAScscore=2(17combina-
tions), with CHA2DS2-VASc score=0 used as the
reference. We did all analyses for one, five, and
10 years of follow-up. In additional Cox regression
models, we included concomitant treatment with anti-
platelet drugs (that is, primary acetylsalicylic acid, clo-
pidogrel,anddipyridamole),toadjustforthispotential
confounder. We also did sensitivity analyses by not
including pulmonary embolism as an outcome.
We used C statistics estimated from Cox regression
models to assess the predictive capability of CHADS2
andCHA2DS2-VAScforthromboembolism,usingthe
method described by Liu and colleagues.
24 C statistics
give a measure of how well the risk prediction scheme
identifies patients who will have a future event. For
estimating C statistics, we analysed CHADS2 and
CHA2DS2-VASc as risk scores (0-6 and 0-9) and as
riskgroups(low,intermediate,andhigh).Wealsoeval-
uated the scores both as categorical and as continuous
covariates. We constructed survival curves, based on
Kaplan-Meier estimates of the probability of remain-
ing free of thromboembolism with a score of 0 and 1,
forthetworiskstratificationschemes.Weconsidereda
twosidedPvalue<0.05tobestatisticallysignificant.In
all Cox models, the model assumptions (that is, pro-
portional hazards, linearity of continuous covariates,
and lack of interactions) were found to be valid. We
used SAS statistical software version 9.1 and Stata sta-
tistical software version 11.0 for the analyses.
RESULTS
Of 121280 patients with non-valvular atrial fibrilla-
tion, 73538 (60.6%) fulfilled the study inclusion cri-
teria (fig 1). Table 1 shows the baseline characteristics
for all patients discharged with non-valvular atrial
fibrillation and for the study population. During the
one, five, and 10 years of follow-up, 9097 (12.4%),
13966 (19.0%), and 15344 (20.9%) of the non-anti-
coagulated patients claimed at least one prescription
for a vitamin K antagonist, and exclusion of these
patients from the time of starting vitamin K antagonist
treatment (censoring) did not alter the results of our
analyses (data not shown). Of the 16406 patients cate-
gorisedbyCHADS2asbeingatlowrisk,6472(39.5%)
were at intermediate risk and 3565 (21.7%) were at
high risk when categorised by CHA2DS2-VASc. Of
Table 3 |All cause mortality rate (95% CI) per 100 person years
Score/risk category 1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
CHADS2:
0 9.33 (8.85 to 9.84) 5.14 (4.95 to 5.33) 4.70 (4.54 to 4.86)
1 24.50 (23.82 to 25.20) 16.61 (16.29 to 16.93) 15.93 (15.65 to 16.22)
2 29.21 (28.30 to 30.14) 21.10 (20.65 to 21.56) 20.57 (20.16 to 20.99)
3 39.41 (38.08 to 40.78) 28.42 (27.74 to 29.11) 27.90 (27.27 to 28.55)
4 43.61 (41.50 to 45.84) 32.69 (31.56 to 33.86) 32.30 (31.22 to 33.41)
5 53.68 (49.10 to 58.70) 38.92 (36.44 to 41.57) 38.90 (36.50 to 41.45)
6 83.30 (67.17 to 103.29) 53.45 (44.56 to 64.12) 51.47 (43.04 to 61.55)
CHADS2:
Low risk (0) 9.33 (8.85 to 9.84) 5.14 (4.95 to 5.33) 4.70 (4.54 to 4.86)
Intermediate risk (1) 24.50 (23.82 to 25.20) 16.61 (16.29 to 16.93) 15.93 (15.65 to 16.22)
High risk (2-6) 35.47 (34.75 to 36.20) 25.46 (25.11 to 25.83) 24.87 (24.53 to 25.21)
CHA2DS2-VASc:
0 4.85 (4.31 to 5.45) 2.56 (2.36 to 2.78) 2.29 (2.12 to 2.47)
1 10.32 (9.61 to 11.08) 5.81 (5.52 to 6.10) 5.33 (5.09 to 5.58)
2 21.17 (20.31 to 22.05) 13.65 (13.27 to 14.04) 12.93 (12.59 to 13.27)
3 27.06 (26.22 to 27.93) 19.11 (18.71 to 19.52) 18.52 (18.16 to 18.89)
4 31.29 (30.27 to 32.35) 22.67 (22.17 to 23.20) 22.23 (21.76 to 22.71)
5 39.45 (37.99 to 40.97) 28.50 (27.75 to 29.27) 28.16 (27.45 to 28.88)
6 44.96 (42.67 to 47.36) 33.00 (31.79 to 34.26) 32.52 (31.37 to 33.71)
7 51.12 (46.91 to 55.70) 37.71 (35.43 to 40.14) 37.98 (35.76 to 40.33)
8 77.74 (65.91 to 91.69) 50.31 (44.07 to 57.43) 48.98 (43.02 to 55.77)
9 105.51 (72.85 to 152.81) 65.77 (47.00 to 92.05) 62.40 (44.59 to 87.33)
CHA2DS2-VASc:
Low risk (0) 4.85 (4.31 to 5.45) 2.56 (2.36 to 2.78) 2.29 (2.12 to 2.47)
Intermediate risk (1) 10.32 (9.61 to 11.08) 5.81 (5.52 to 6.10) 5.33 (5.09 to 5.58)
High risk(2-9) 30.46 (29.97 to 30.96) 21.07 (20.83 to 21.30) 20.32 (20.10 to 20.54)
Years of follow-up
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Fig 2 | Kaplan-Meier estimate of probability of remaining free
of thromboembolism with CHADS2 score 0 and 1. Only
patients with CHADS2 scores 0 and 1 were included, and
patients were censored at death for causes other than
thromboembolism
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intermediate risk, 21999 (92.7%) were at high risk
when categorised by CHA2DS2-VASc.
Table 2 shows rates of thromboembolism per
100 person years according to CHADS2 and
CHA2DS2-VASc risk scores at one, five, and 10 years
of follow-up. The thromboembolic rates after one year
offollow-upinthelowriskcategory(score=0)were1.67
(95%confidenceinterval1.47to1.89)forCHADS2and
0.78 (0.58 to 1.04) for CHA2DS2-VASc. In the inter-
mediateriskcategory(score=1),therateofthromboem-
bolism per 100 person years was 4.75 (4.45 to 5.07) for
CHADS2 and 2.01 (1.70 to 2.36) for CHA2DS2-VASc.
This risk pattern was generally sustained at five and
10 years of follow-up; patients classified as being at
intermediate risk by CHADS2 had a higher rate of
thromboembolism (approximately 3.6) than did those
classified as being at intermediate risk by CHA2DS2-
VASc (approximately 1.5). The high risk categories
(score≥2) as determined by either CHADS2 or
CHA2DS2-VASc had markedly increased rates of
thromboembolism compared with the low or inter-
mediate risk categories.
We also estimated rates of thromboembolism in the
vitamin K antagonist treated patients. In all risk cate-
gories, except for patients classified with CHA2DS2-
VASc score=0, the thromboembolic rate was lower in
the vitamin K antagonist treated patients. In these
patients, thromboembolic rates after one year of fol-
low-up in the low risk category were 1.27 (1.06 to
1.53) per 100 person years for CHADS2 and 0.81
(0.56to1.17)forCHA2DS2-VASc.Intheintermediate
risk category, the rates were 2.27 (2.02 to 2.56) for
CHADS2and1.23(0.98to1.56)forCHA2DS2-VASc.
Table3showsmortalityratesaccordingtoCHADS2
andCHA2DS2-VAScscores.Wefoundaclearrelation
between increasing CHADS2 and CHA2DS2-VASc
score and increasing mortality rates. The low risk and
intermediate risk categories as determined by
CHA2DS2-VASc had much lower mortality rates
than did patients categorised in these two risk groups
by CHADS2.
Table 4 shows rates of thromboembolism according
totheriskfactorscomposingCHADS2scores0,1,and
2; table 5 shows hazard ratios from Cox proportional
hazard analysis. The risk associated with CHADS2
score=1 depended on the specific conditions (risk fac-
tors) composing the score. The risk factor associated
with the highest risk was age≥75 (hazard ratio 3.52,
95% confidence interval 3.05 to 4.07, at one year’s
Table 4 |Event rates (95% CI) for hospital admission and death due to thromboembolism*
per 100 person years by CHADS2 score and by covariates
Score and covariates 1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
CHADS2 score=0 1.67 (1.47 to 1.89) 1.28 (1.19 to 1.38) 1.24 (1.16 to 1.33)
CHADS2 score=1:
Heart failure 2.80 (1.81 to 4.34) 2.57 (2.00 to 3.30) 2.31 (1.82 to 2.93)
Hypertension 2.42 (2.04 to 2.87) 1.95 (1.77 to 2.16) 1.94 (1.77 to 2.13)
Age≥75 5.97 (5.55 to 6.41) 4.77 (4.55 to 5.00) 4.64 (4.44 to 4.85)
Diabetes mellitus 3.00 (1.97 to 4.55) 2.37 (1.84 to 3.05) 2.42 (1.93 to 3.04)
CHADS2 score=2:
Diabetes + heart failure 6.36 (3.31 to 12.23) 6.36 (4.33 to 9.34) 5.96 (4.12 to 8.63)
Diabetes + hypertension 2.81 (1.80 to 4.41) 2.75 (2.14 to 3.53) 2.78 (2.21 to 3.50)
Diabetes + age≥75 7.83 (6.13 to 10.01) 5.66 (4.75 to 6.74) 5.37 (4.52 to 6.36)
Heartfailure+hypertension 4.44 (3.23 to 6.10) 3.44 (2.80 to 4.22) 3.28 (2.71 to 3.97)
Heart failure + age≥75 6.63 (5.77 to 7.62) 5.56 (5.06 to 6.10) 5.50 (5.03 to 6.02)
Hypertension + age≥75 6.93 (6.30 to 7.62) 5.65 (5.31 to 6.01) 5.47 (5.15 to 5.80)
Previous
thromboembolism
15.46 (13.41 to 17.83) 8.25 (7.40 to 9.20) 7.74 (6.98 to 8.57)
*Includes peripheral artery embolism, ischaemic stroke, and pulmonary embolism.
Table 5 |Hazard ratios for hospital admission and death due to thromboembolism* by combinations of covariates
composing CHADS2 scores 1 and 2
Score and covariates
1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
CHADS2 score=0 1.00 1.00 1.00
CHADS2 score=1:
Heart failure 1.67 (1.06 to 2.63) 0.03 1.99 (1.53 to 2.58) <0.0001 1.84 (1.43 to 2.35) <0.0001
Hypertension 1.45 (1.17 to 1.79) 0.0006 1.52 (1.34 to 1.73) <0.0001 1.56 (1.39 to 1.74) <0.0001
Age≥75 3.52 (3.05 to 4.07) <0.0001 3.62 (3.31 to 3.96) <0.0001 3.59 (3.31 to 3.90) <0.0001
Diabetes mellitus 1.79 (1.16 to 2.77) 0.009 1.84 (1.41 to 2.39) <0.0001 1.93 (1.53 to 2.45) <0.0001
CHADS2 score=2:
Diabetes + heart failure 3.74 (1.93 to 7.28) 0.0001 4.75 (3.21 to 7.03) <0.0001 4.52 (3.10 to 6.59) <0.0001
Diabetes + hypertension 1.67 (1.05 to 2.67) 0.03 2.11 (1.62 to 2.74) <0.0001 2.17 (1.71 to 2.76) <0.0001
Diabetes + age≥75 4.57 (3.47 to 6.02) <0.0001 4.16 (3.44 to 5.04) <0.0001 3.98 (3.31 to 4.79) <0.0001
Heart failure + hypertension 2.63 (1.87 to 3.70) <0.0001 2.61 (2.09 to 3.24) <0.0001 2.55 (2.08 to 3.12) <0.0001
Heart failure + age≥75 3.84 (3.19 to 4.64) <0.0001 4.04 (3.58 to 4.56) <0.0001 4.04 (3.61 to 4.53) <0.0001
Hypertension + age≥75 4.08 (3.48 to 4.77) <0.0001 4.22 (3.83 to 4.66) <0.0001 4.14 (3.78 to 4.53) <0.0001
Previous thromboembolism 9.13 (7.55 to 11.04) <0.0001 6.30 (5.52 to 7.19) <0.0001 6.05 (5.35 to 6.83) <0.0001
Results from Cox proportional hazard analyses; CHADS2 score=0 was reference.
*Includes peripheral artery embolism, ischaemic stroke, and pulmonary embolism.
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the lowest thromboembolic risk (1.45, 1.17 to 1.79, at
one year’s follow-up). In patients with CHADS2
score=2, previous thromboembolism as a single risk
factor clearly carried the highest risk. Multivariable
analyses including treatment with antiplatelet drugs
yielded very similar results (web extra table A). Figure
2 shows thromboembolic-free survival curves for
CHADS2 scores 0 and 1.
Table 6 shows rates of thromboembolism according
toriskfactorscomposingCHA2DS2-VAScscores0,1,
and 2; table 7 shows relative risks (hazard ratios).
Again, the risk associated with a particular
CHA2DS2-VASc score was strongly dependent on
the specific conditions (risk factors) composing the
score.ForpatientswithCHA2DS2-VAScscore=1,dia-
betes was associated with the highest thromboembolic
rate (3.47, 1.65 to 7.27) and age 65-74 had the second
highestrate(2.88,2.29to3.62)atoneyearoffollow-up.
In patients with CHA2DS2-VASc score=2, previous
thromboembolism as a single risk factor was clearly
associated with the highest risk, followed by age≥75.
Again, multivariable analyses including treatment
with antiplatelet drugs yielded very similar results
(web extra table B). Figure 3 shows thromboembolic-
free survival curves for CHA2DS2-VASc scores 0 and
1. The thromboembolic rate with CHA2DS2-VASc
score=1 was lower than that with CHADS2 score=1,
so the thromboembolic rate associated with one speci-
fic risk factor (for example, diabetes) was lower in the
intermediate risk category (score=1) determined by
CHA2DS2-VASc than by CHADS2. Likewise, the
thromboembolic rate with CHA2DS2-VASc score=0
was lower than with CHADS2 score=0; using score=0
as the reference, the hazard ratio with a specific risk
factor was higher in the intermediate risk category
determined by CHA2DS2-VASc than by CHADS2.
Table 8 shows how accurately CHADS2 and
CHA2DS2-VASc identified patients who had a throm-
boembolism during follow-up (C statistics based on
Cox regression models); scores were entered in the
analysis as categorical or continuous variables. The
predictive abilities with CHADS2 and CHA2DS2-
VASc analysed as scores (0-6 and 0-9) were very simi-
lar, whereas the predictive ability of CHA2DS2-VASc
was clearly superior to CHADS2 for categorisation of
patients into risk groups (low, intermediate, and high
risk).Atone,five,and10yearsoffollow-up,Cstatistics
withCHADS2were0.722,0.796,and0.812;thecorre-
sponding C statistics with CHA2DS2-VASc were
0.850, 0.880, and 0.888. The 95% confidence intervals
for CHADS2 and CHA2DS2-VASc did not overlap.
Of the thromboembolic events representing the pri-
marystudyoutcome,pulmonaryembolismcomprised
7.7%.Sensitivityanalysesexcludingpulmonaryembo-
lismfromthestudyoutcomeyieldresultssimilartothe
main findings (web extra tables C and D). The predic-
tive abilities (C statistics) for categorising patients into
risk groupsat one,five, and10 yearsoffollow-upwere
0.711,0.789,and0.806forCHADS2and0.845,0.877,
and 0.885 for CHA2DS2-VASc. Again, the 95% confi-
dence intervals did not overlap.
DISCUSSION
This nationwide study used the largest real world
cohort of non-anticoagulated patients with non-
Table 6 |Event rates (95% CI) for hospital admission and death due to thromboembolism*
per 100 person years by CHA2DS2-VASc score and by covariates
Score and covariates 1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
CHA2DS2-VASc score= 0 0.78 (0.58 to 1.04) 0.69 (0.59 to 0.81) 0.66 (0.57 to 0.76)
CHA2DS2-VASc score=1:
Heart failure 1.50 (0.37 to 5.98) 2.35 (1.30 to 4.24) 1.78 (0.99 to 3.21)
Hypertension 2.14 (1.46 to 3.15) 1.60 (1.26 to 2.01) 1.49 (1.21 to 1.84)
Diabetes mellitus 3.47 (1.65 to 7.27) 2.28 (1.42 to 3.66) 2.02 (1.29 to 3.16)
Vascular disease 0.75 (0.24 to 2.33) 1.40 (0.91 to 2.15) 1.47 (1.01 to 2.12)
Age 65-74 2.88 (2.29 to 3.62) 2.13 (1.85 to 2.46) 2.09 (1.83 to 2.38)
Female sex 1.24 (0.89 to 1.73) 0.86 (0.70 to 1.06) 0.82 (0.68 to 1.00)
CHA2DS2-VASc score=2:
Diabetes + heart failure 4.53 (0.64 to 32.17) 3.52(1.13to10.91) 3.83 (1.44 to 10.21)
Diabetes + hypertension 3.29 (1.37 to 7.91) 1.79 (0.93 to 3.44) 1.94 (1.10 to 3.42)
Diabetes + age 65-74 1.49 (0.48 to 4.61) 1.92 (1.11 to 3.30) 1.98 (1.21 to 3.22)
Diabetes + vascular disease 0 1.06 (0.15 to 7.55) 1.80 (0.45 to 7.19)
Diabetes + female sex 1.11 (0.16 to 7.85) 0.62 (0.16 to 2.49) 1.23 (0.51 to 2.96)
Heart failure + hypertension 4.11 (1.96 to 8.62) 3.19 (1.98 to 5.14) 2.81 (1.79 to 4.41)
Heart failure + age 65-74 1.84 (0.69 to 4.90) 2.49 (1.55 to 4.01) 2.46 (1.59 to 3.82)
Heart failure + vascular disease 3.55 (0.50 to 25.17) 1.91 (0.48 to 7.66) 1.49 (0.37 to 5.97)
Heart failure + female sex 0 0.55 (0.08 to 3.87) 0.87 (0.22 to 3.49)
Hypertension + age 65-74 2.54 (1.74 to 3.70) 2.22 (1.79 to 2.76) 2.30 (1.89 to 2.78)
Hypertension + vascular disease 1.56 (0.70 to 3.48) 1.48 (0.96 to 2.30) 1.52 (1.02 to 2.24)
Hypertension + female sex 1.84 (1.09 to 3.11) 1.48 (1.09 to 2.02) 1.43 (1.08 to 1.89)
Age 65-74 + vascular disease 2.90 (1.72 to 4.89) 2.47 (1.82 to 3.35) 2.54 (1.93 to 3.35)
Age 65-74 + female sex 2.82 (2.21 to 3.60) 2.10 (1.81 to 2.45) 2.06 (1.80 to 2.36)
Vascular disease + female sex 2.87 (0.93 to 8.91) 1.95 (0.93 to 4.08) 2.26 (1.21 to 4.19)
Age≥75 4.75 (4.14 to 5.44) 4.37 (4.02 to 4.75) 4.27 (3.94 to 4.62)
Previous thromboembolism 16.07 (11.64 to 22.18) 7.87(6.12to10.11) 6.98 (5.50 to 8.85)
*Includes peripheral artery embolism, ischaemic stroke, and pulmonary embolism.
Years of follow-up
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Fig 3 | Kaplan-Meier estimate of probability of remaining free
of thromboembolism with CHA2DS2-VASc score 0 and 1. Only
patients with CHA2DS2-VASc scores 0 and 1 were included,
and patients were censored at death for causes other than
thromboembolism
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thatCHA2DS2-VAScperformedbetterthanCHADS2
for categorisation of patients into risk groups (low,
intermediate, and high risk) for stroke and for identifi-
cation of patients at “truly low risk” (score=0). With a
CHADS2scoreof0or1,thethromboembolicriskwas
still appreciable. Also, not all risk factors composing
CHADS2 score=1 were associated with an equal risk;
a particularly high risk was associated with age≥75.
Patients with CHA2DS2-VASc score=1 had a lower
rate of thromboembolism, which would seem more
“truly moderate.” Again, not all risk factors in
CHA2DS2-VASc score=1 were associated with an
equal risk, and diabetes and age 65-74 were associated
with the highest thromboembolic rates. With
CHADS2 or CHA2DS2-VASc score=2, again the
thromboembolic rates were strongly dependent on
the specific covariates composing the score, and the
risk associated with previous thromboembolism was
markedly increasedcomparedwith all other combina-
tions of risk factors. We also found that with
CHA2DS2-VASc score=0 the risk was “truly low”
and no reduction in thromboembolic rate occurred
with vitamin K antagonist treatment, whereas the
thromboembolic rate was reduced in vitamin K
antagonist treated patients with CHADS2 scores 0-1
and CHA2DS2-VASc score=1.
Implications of findings
The advantage of CHADS2 is its simplicity, although
its limitations are well recognised.
25 CHADS2 was
developed by amalgamation of risk schemes derived
from clinical trial cohorts; it was initially validated in
a cohort of patients with atrial fibrillation admitted to
hospital, with event rates reflecting clinical practice
more than a decade ago.
11 Even the “C” in CHADS2
has been debated, as a history of congestive heart fail-
ure does not seem to be an independent risk factor for
thromboembolism.
21126Theriskofthromboembolism
increases with increasing age above 65 years,
27 rising
approximately 1.5-fold per decade.
2 The increased
effect of age≥75 as a single high risk factor was sug-
gestedbycohortanalysesandarecentsemi-systematic
review,
628and thisfindingwasconfirmedinourstudy.
Otherrisk factorssuch asfemale sex and previousvas-
cular disease have been recognised.
1229-32 Our study
Table 7 |Hazard ratios for hospital admission and death due to thromboembolism* by combinations of covariates
composing CHA2DS2-VASc scores 1 and 2
Score and covariates
1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
CHA2DS2-VASc score=0 1.00 1.00 1.00
CHA2DS2-VASc score=1:
Heart failure 1.92 (0.47 to 7.91) 0.37 3.39 (1.84 to 6.26) <0.0001 2.69 (1.47 to 4.95) 0.001
Hypertension 2.76 (1.70 to 4.48) <0.0001 2.32 (1.75 to 3.07) <0.0001 2.26 (1.75 to 2.92) <0.0001
Diabetes mellitus 4.46 (2.01 to 9.89) 0.0002 3.31 (2.00 to 5.46) <0.0001 3.03 (1.89 to 4.86) <0.0001
Vascular disease 0.97 (0.30 to 3.11) 0.96 2.04 (1.29 to 3.22) 0.002 2.22 (1.49 to 3.30) <0.0001
Age 65-74 3.68 (2.54 to 5.34) <0.0001 3.07 (2.48 to 3.80) <0.0001 3.12 (2.57 to 3.78) <0.0001
Female sex 1.60 (1.02 to 2.49) 0.04 1.25 (0.96 to 1.63) 0.10 1.24 (0.98 to 1.57) 0.08
CHA2DS2-VASc score=2:
Diabetes + heart failure 5.80 (0.80 to 42.09) 0.08 5.13 (1.64 to 16.07) 0.005 5.79 (2.15 to 15.59) 0.0005
Diabetes + hypertension 4.23 (1.68 to 10.65) 0.002 2.58 (1.32 to 5.05) 0.006 2.90 (1.62 to 5.21) 0.0003
Diabetes + age 65-74 1.89 (0.59 to 6.09) 0.29 2.75 (1.56 to 4.85) 0.0005 2.94 (1.77 to 4.90) <0.0001
Diabetes + vascular disease – 0.98 1.54 (0.22 to 10.98) 0.67 2.69 (0.67 to 10.82) 0.16
Diabetes + female sex 1.42 (0.20 to 10.30) 0.73 0.90 (0.22 to 3.64) 0.88 1.86 (0.76 to 4.51) 0.17
Heart failure + hypertension 5.26 (2.37 to 11.66) <0.0001 4.56 (2.76 to 7.53) <0.0001 4.19 (2.62 to 6.72) <0.0001
Heart failure + age 65-74 2.33 (0.84 to 6.47) 0.11 3.55 (2.15 to 5.86) <0.0001 3.65 (2.30 to 5.78) <0.0001
Heartfailure+vasculardisease 4.55 (0.63 to 33.02) 0.13 2.78 (0.69 to 11.22) 0.15 2.26 (0.56 to 9.09) 0.25
Heart failure + female sex – 0.97 0.79 (0.11 to 5.67) 0.82 1.32 (0.33 to 5.32) 0.70
Hypertension + age 65-74 3.26 (2.02 to 5.25) <0.0001 3.21 (2.45 to 4.20) <0.0001 3.44 (2.71 to 4.37) <0.0001
Hypertension + vascular
disease
2.02 (0.86 to 4.73) 0.11 2.14 (1.35 to 3.42) 0.001 2.28 (1.50 to 3.46) 0.0001
Hypertension + female sex 2.37 (1.30 to 4.32) 0.005 2.15 (1.52 to 3.04) <0.0001 2.16 (1.58 to 2.95) <0.0001
Age 65-74 + vascular disease 3.70 (2.03 to 6.74) <0.0001 3.56 (2.52 to 5.02) <0.0001 3.80 (2.79 to 5.18) <0.0001
Age 65-74 + female sex 3.61 (2.46 to 5.28) <0.0001 3.04 (2.44 to 3.79) <0.0001 3.11 (2.55 to 3.78) <0.0001
Vascular disease + female sex 3.69 (1.15 to 11.88) 0.03 2.81 (1.32 to 5.99) 0.008 3.38 (1.79 to 6.38) 0.0002
Age≥75 5.96 (4.32 to 8.23) <0.0001 6.16 (5.14 to 7.38) <0.0001 6.21 (5.27 to 7.33) <0.0001
Previous thromboembolism 20.44 (13.23 to 31.57) <0.0001 11.27 (8.37 to 15.18) <0.0001 10.44 (7.91 to 13.78) <0.0001
Results from Cox proportional-hazard analyses; CHA2DS2-VASc score=0 was reference.
*Includes peripheral artery embolism, ischaemic stroke, and pulmonary embolism.
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thromboembolism; in patients with CHA2DS2-VASc
score=1, female sex increased the risk of thromboem-
bolism at one year of follow-up and vascular disease
increased thromboembolic risk at five and 10 years of
follow-up.
Because of the benefit of oral anticoagulation over
aspirin, in patients with atrial fibrillation and
CHADS2score=2theclinicalimpetuswouldbetoanti
coagulate.
5-7 With CHADS2 scores 0-1, or where a
morecomprehensivestrokeriskandvitaminKantago-
nistrisk/benefitassessmentisnecessary,aneedclearly
exists to consider other risk factors not included in the
CHADS2 score. This large study in a non-anti-
coagulated cohort with non-valvular atrial fibrillation
clearly shows advantages of CHA2DS2-VASc for
further refinement of thromboembolic risk stratifica-
tion, with improvements in C statistics for identifica-
tion of patients at low, intermediate, and high risk of
thromboembolism and a convincing identification of
thosewithatrulylowriskofthromboembolism.Useof
CHA2DS2-VASc could therefore simplify thrombo-
prophylaxis, with CHA2DS2-VASc score=0 identify-
ing patients at truly low risk for whom no
antithrombotic treatment may be considered. With
CHA2DS2-VASc score=1, oral anticoagulation can
be used, given the limited evidence for the efficacy of
aspirin (which also has a potential for bleeding
8) and
with consideration of the future availability of new
oralanticoagulantdrugsthatcanovercometheclinical
disadvantages of vitamin K antagonists (for example,
withouttheneedformonitoringofanticoagulationand
withlessriskofbleeding).Also,whentheintermediate
riskcategorywasdefinedasCHA2DS2-VAScscore=1,
only 11.2% of patients were categorised in this group,
compared with 32.3% when the CHADS2 score=1
definition was used. Based on the 2006 ACC/AHA/
ESC guidelines, which recommend vitamin K antago-
nistoraspirinforthisintermediateriskcategory,using
the CHADS2 score rather than the CHA2DS2-VASc
score would open more patients to the uncertainty of
vitaminKantagonistoraspirinandcouldevenresultin
aspirin being used instead of vitamin K antagonist, as
the guidelines do not provide definitive
recommendations. Finally, the decision to anti-
coagulate is based not only on thromboembolic risk
but also on the risk of bleeding, and the European
guidelines on atrial fibrillation incorporate a new
bleeding prediction scheme to help with this decision
making.
33
Limitations of study
The main limitation of this study was inherent to its
observational nature. We had no information on the
reason(s)forabsenceofvitaminKantagonisttreatment
in this specific cohort of patients with non-valvular
atrial fibrillation, and we could not differentiate
between paroxysmal, persistent, and permanent atrial
fibrillation and atrial fibrillation that had been trig-
gered by a single episode of acute illness. Even though
the positive predictive value of the diagnosis of atrial
fibrillationisveryhighintheregistry(99%),
29anddata
onprescriptionclaimsareaccurate,
16retrospectivestu-
dies maybe affected by misclassification and inclusion
bias—forexample,byincludingonlypatientsadmitted
to hospital with atrial fibrillation we might have
increased the proportion of patients who were at
higher risk of thromboembolic events and death.
Furthermore, to account for treatment started in rela-
tion to the admission for atrial fibrillation, we defined
thestudybaselineatdaysevenfromdischarge,thereby
excluding2.5%ofthepopulationwithatrialfibrillation
from the study.
The frequencies of risk factors in the study popula-
tionwerealsounderestimated,asweidentifiedpatients
withheartfailure,hypertension,anddiabetesfrompre-
scriptionclaimsandthusdidnotdetectpatientstreated
with diet control and lifestyle interventions alone.
Therefore, the estimated thrombotic risk must be
applied with caution in these populations. Further-
more, we were not able to account for effects of smok-
ing, family history of thromboembolism, alcohol
intake, or body mass index. The outcome diagnoses
of stroke and pulmonary embolism have previously
been validated in the registry; the positive predictive
valueofischaemicstroke(I63)was97%,haemorrhagic
strokesonlycomprised5.8%oftheunspecifiedstrokes
(I64), and pulmonary embolism (I26) had a positive
predictive value of 82.1%.
2123 However, patients with
previousstrokes were excluded in the validationstudy
andinourstudytheywerenot,sotheriskremainsthat
some of the stroke outcomes in this study may in fact
have been recoding of old strokes, which again would
lead to overestimation of the observed high risk asso-
ciated with previous stroke.
Conclusions
The risk associated with a specific risk score in both
CHADS2 and CHA2DS2-VASc depends on the risk
factors composing the score. CHA2DS2-VASc per-
formed better than CHADS2 in predicting patients at
high risk and can also be used to identify patients with
non-valvular atrial fibrillation with a truly low risk of
thromboembolism.
Table 8 |C statistics (95% CI) based on Cox regression models with covariates analysed as
categorical or continuous variables
1 year’s follow-up 5 years’ follow-up 10 years’ follow-up
Covariates analysed as categorical variables
CHADS2; score 0-6 0.663 (0.634 to 0.691) 0.762 (0.744 to 0.780) 0.781 (0.764 to 0.797)
CHADS2; 3 groups 0.722 (0.694 to 0.748) 0.796 (0.778 to 0.812) 0.812 (0.796 to 0.827)
CHA2DS2-VASc; score 0-9 0.661 (0.633 to 0.690) 0.758 (0.740 to 0.776) 0.777 (0.760 to 0.793)
CHA2DS2-VASc; 3 groups 0.850 (0.829 to 0.871) 0.880 (0.866 to 0.893) 0.888 (0.875 to 0.900)
Covariates analysed as continuous variables
CHADS2; score 0-6 0.691 (0.663 to 0.719) 0.787 (0.770 to 0.804) 0.804 (0.788 to 0.819)
CHADS2; 3 groups 0.722 (0.694 to 0.748) 0.796 (0.778 to 0.812) 0.812 (0.796 to 0.827)
CHA2DS2-VASc; score 0-9 0.682 (0.653 to 0.709) 0.775 (0.757 to 0.793) 0.792 (0.776 to 0.808)
CHA2DS2-VASc; 3 groups 0.852 (0.830 to 0.873) 0.882 (0.868 to 0.895) 0.890 (0.877 to 0.902)
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Thromboembolic risk stratification of patients with non-valvular atrial fibrillation is essential
for selection of optimal antithrombotic treatment
The most commonly used risk stratification scheme is CHADS2;C H A 2DS2-VASc was
developed to complement CHADS2 by considering additional thromboembolic risk modifiers
WHAT THIS STUDY ADDS
CHA2DS2-VASc is more valid for stroke prediction in patientscategorised as being at low and
intermediate risk by the CHADS2 scheme
Thisisclinically important,asmanyofthe patientsatlow riskaccordingtoCHADS2arenot at
“truly low risk” and treatment guidelines are not conclusive for those at intermediate risk
The importance of each component of the CHADS2 and CHA2DS2-VASc scores for
thromboembolism risk has been estimated
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